Select language:
On this page

    Last updated: November 2022


    Prescription under medical supervision


    Therapeutic action

    • Antiretroviral, HIV-1 non nucleoside reverse transcriptase inhibitor


    • HIV-1 infection in neonates, in combination with other antiretrovirals

    Forms and strengths

    • 50 mg/5 ml oral suspension


    The daily dose is administered in 2 divided doses.

    • Child under one month:



    50 mg/5 ml oral suspension

    (10 mg/ml)

    2 to < 3 kg 1.5 ml x 2
    3 to < 4 kg 2 ml x 2
    4 to < 5 kg 3 ml x 2 



    • Change to lopinavir/ritonavir granules (at 2 weeks of age) or dolutegravir dispersible tablet (at 4 weeks of age). 

    Contra-indications, adverse effects, precautions

    • May cause:
      • cutaneous reactions sometimes severe (Stevens-Johnson and Lyell syndromes), hepatic disorders possibly severe (fulminant hepatitis) and haematological disorders. In these cases, stop nevirapine immediately and permanently;
      • gastrointestinal disturbances (take with food to increase tolerance), headache, myalgia.
    • Avoid combination with rifampicin (decreases the efficacy of nevirapine).


    • Nevirapine is also used for prophylactic treatment to reduce mother-to-child transmission and treatment of HIV-1 infection in children and adults, in combination with other antiretrovirals. Check national recommendations.


    Below 25 °C
    Once opened, oral suspension keeps for 2 months maximum.